Atlas Marine Parts signed a 60-month equipment lease on July 1, 2024 for a production cell used in marine components. Payments are fixed at $1,335 per month, the asset is not specialized, and the CFO asks why analysts adjusted EBITDA and leverage. Under ASC 842 and IFRS 16, which treatment is most defensible for lessee analysis?
